Trial reportPsychosomatic medicine2013
Effects of medical comorbidity on anxiety treatment outcomes in primary care.
Trial report in Psychosomatic medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00347269 (Coordinated Anxiety Learning and Management), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Behavioral therapy in migraine: Expanding the therapeutic arsenal.European journal of neurology · 2024Review
- Coping, social support, and anxiety in people with mast cell disorders.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Article
- Heart-Focused Anxiety Among Latinxs in Primary Care: Relations to Anxiety, Depression, Pain, and Functional Impairment.The Journal of nervous and mental disease · 2019Article
- Evidence-Based Psychotherapy in Primary Care.Focus (American Psychiatric Publishing) · 2017Review
- Anxiety Disorders and General Medical Conditions: Current Research and Future Directions.Focus (American Psychiatric Publishing) · 2017Review
- Anxiety disorders and physical comorbidity: increased prevalence but reduced relevance of specific risk factors for hospital-based mortality during a 12.5-year observation period in general hospital admissions.European archives of psychiatry and clinical neuroscience · 2015Article
- Treatment-refractory anxiety; definition, risk factors, and treatment challenges.Dialogues in clinical neuroscience · 2015Review
- Anxiety and depressive symptoms and medical illness among adults with anxiety disorders.Journal of psychosomatic research · 2015Article
- Treating anxiety in the presence of medical comorbidity: calmly moving forward.Psychosomatic medicine · 2013Article
- Prevalence and treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and co-morbid severe health anxiety.International journal of clinical and health psychology : IJCHPArticle
Corrections and comments
- Commented on by
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate the effects of medical comorbidity on anxiety treatment outcomes.
methodsData were analyzed from 1004 primary care patients enrolled in a trial of a collaborative care intervention for anxiety. Linear-mixed models accounting for baseline characteristics were used to evaluate the effects of overall medical comorbidity (two or more chronic medical conditions [CMCs] versus fewer than two CMCs) and specific CMCs (migraine, asthma, and gastrointestinal disease) on anxiety treatment outcomes at 6, 12, and 18 months.
resultsAt baseline, patients with two or more CMCs (n = 582; 58.0%) reported more severe anxiety symptoms (10.5 [95% confidence interval {CI} = 10.1-10.9] versus 9.5 [95% CI = 9.0-10.0], p = .003) and anxiety-related disability (17.6 [95% CI = 17.0-18.2] versus 16.0 [95% CI = 15.3-16.7], p = .001). However, their clinical improvement was comparable to that of patients with one or zero CMCs (predicted change in anxiety symptoms = -3.9 versus -4.1 at 6 months, -4.6 versus -4.4 at 12 months, -4.9 versus -5.0 at 18 months; predicted change in anxiety-related disability = -6.4 versus -6.9 at 6 months, -6.9 versus -7.3 at 12 months, -7.3 versus -7.5 at 18 months). The only specific CMC with a detrimental effect was migraine, which was associated with less improvement in anxiety symptoms at 18 months (predicted change = -4.1 versus -5.3).
conclusionsEffectiveness of the anxiety intervention was not significantly affected by the presence of multiple CMCs; however, patients with migraine displayed less improvement at long-term follow-up. Trial Registration ClinicalTrials.com Identifier: NCT00347269.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.